Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | Director | June 26, 2026 | June 26, 2026 |
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | Director | April 02, 2026 | April 06, 2026 |
| Karuna Therapeutics, Inc.KRTX · Entity 92934 | Chief Financial Officer | August 22, 2023 | August 24, 2023 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Chief Financial Officer | February 02, 2026 | February 04, 2026 |
| scPharmaceuticals Inc.SCPH · Entity 74456 | Chief Financial Officer | January 17, 2018 | January 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Contineum Therapeutics, Inc.
Report date June 26, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.19 · Expires 2036-06-25 | Direct | 19,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 19,000 · Balance 19,000 F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
Harmony Biosciences Holdings, Inc.
Report date April 02, 2026 · Filed April 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $27.74 · Expires 2036-04-02 | Direct | 17,710 |
Reported balance
After 2026-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-02 · Grant · Acquired 17,710 · Balance 17,710 F1: The stock option shall vest in 36 equal monthly installments beginning on May 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in 36 equal monthly installments beginning on May 2, 2026.
Karuna Therapeutics, Inc.
Report date August 22, 2023 · Filed August 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,487 |
Ending reported balance
After 2023-08-22 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2023-08-22 · Exercise / conversion · Acquired 1,500 · Balance 31,987 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. Row 2 · 2023-08-22 · Sale · Disposed 80 · Balance 31,907 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.31 to $174.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) to this Form 4. Row 3 · 2023-08-22 · Sale · Disposed 855 · Balance 31,052 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.32 to $175.31, inclusive. Row 4 · 2023-08-22 · Sale · Disposed 505 · Balance 30,547 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.32 to $176.30, inclusive. Row 5 · 2023-08-22 · Sale · Disposed 60 · Balance 30,487 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.59 to $176.61, inclusive. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2029-03-21 | Direct | 93,226 |
Reported balance
After 2023-08-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-22 · Exercise / conversion · Disposed 1,500 · Balance 93,226 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F6: This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.31 to $174.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.32 to $175.31, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.32 to $176.30, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.59 to $176.61, inclusive.
F6: This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.
Rapport Therapeutics, Inc.
Report date February 02, 2026 · Filed February 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.75 · Expires 2036-02-02 | Direct | 148,000 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 148,000 · Balance 148,000 F1: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.
scPharmaceuticals Inc.
Report date January 17, 2018 · Filed January 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.23 · Expires 2028-01-17 | Direct | 42,616 |
Reported balance
After 2018-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-17 · Grant · Acquired 42,616 · Balance 42,616 F1: The option shares vest over a four-year period, at a rate of 25% on the first anniversary of the grant date, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares are fully vested on the fourth anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares vest over a four-year period, at a rate of 25% on the first anniversary of the grant date, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares are fully vested on the fourth anniversary of the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CinCor Pharma, Inc.
Report date February 24, 2023 · Filed February 24, 2023
Section 16 reporting ended · disclosed 2023-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.82 · Expires 2031-06-17 | Direct | 0 |
Reported balance
After 2023-02-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-24 · Disposition to issuer · Disposed 36,324 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2031-12-09 | Direct | 0 |
Reported balance
After 2023-02-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-24 · Disposition to issuer · Disposed 58,823 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 26, 2026 21:43 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0001628280-26-045837 · wk-form4_1782510226.xml · derivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Class A Common Stock · 19,000 shares Expires 2036-06-25 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| April 02, 2026 Filed Apr 6, 2026 20:14 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 17,710 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001579829-26-000003 · form4-04062026_080459.xml · derivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,710 Underlying: Common Stock · 17,710 shares Expires 2036-04-02 F1 · derivative.exercise_date: The stock option shall vest in 36 equal monthly installments beginning on May 2, 2026. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:12 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 148,000 | $0.00 Strike: $27.75 | $0.00 |
DisclosureSEC source: 0001193125-26-037587 · ownership.xml · derivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,000 Underlying: Common Stock · 148,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 26, 2025 Filed Jun 26, 2025 21:44 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 14,750 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001437749-25-021369 · rdgdoc.xml · derivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,750 Underlying: Class A Common Stock · 14,750 shares Expires 2035-06-25 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 21:13 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | PurchaseCommon Stock | 100 | $9.98 | $998.00 |
DisclosureSEC source: 0000950170-25-038878 · ownership.xml · nonDerivative · entry 2 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 21:13 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | PurchaseCommon Stock | 9,900 | $10.10 | $99,990.00 |
DisclosureSEC source: 0000950170-25-038878 · ownership.xml · nonDerivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,900 Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 142,000 | $0.00 Strike: $16.60 | $0.00 |
DisclosureSEC source: 0000950170-25-013754 · ownership.xml · derivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,000 Underlying: Common Stock · 142,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 23:35 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 81,366 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071527 · ownership.xml · derivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,366 Underlying: Common Stock · 81,366 shares Expires 2034-06-05 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on June 6, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 24, 2024 Filed May 29, 2024 21:56 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 6,350 | $0.00 Strike: $15.76 | $0.00 |
DisclosureSEC source: 0001437749-24-018622 · rdgdoc.xml · derivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,350 Underlying: Class A Common Stock · 6,350 shares Expires 2034-05-23 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended. One-third of the option shares vest on May 20, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| May 20, 2024 Filed May 20, 2024 23:00 UTC | Contineum Therapeutics, Inc. CTNM · Entity 5311 | GrantStock Option (right to buy) · Derivative | 23,150 | $0.00 Strike: $15.71 | $0.00 |
DisclosureSEC source: 0001437749-24-017719 · rdgdoc.xml · derivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,150 Underlying: Class A Common Stock · 23,150 shares Expires 2034-05-19 F1 · derivative.exercise_date: Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Plan. One-third of the option shares vest and become exercisable on May 20, 2025, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 20:49 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 1,500 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0000950170-23-044413 · ownership.xml · derivative · entry 6 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,226 Underlying: Common Stock · 1,500 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F6 · derivative.exercise_date: This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 20:49 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 60 | $176.60 | $10,596.00 |
DisclosureSEC source: 0000950170-23-044413 · ownership.xml · nonDerivative · entry 5 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,487 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.59 to $176.61, inclusive. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 20:49 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 505 | $175.59 | $88,672.95 |
DisclosureSEC source: 0000950170-23-044413 · ownership.xml · nonDerivative · entry 4 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,547 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.32 to $176.30, inclusive. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 20:49 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 855 | $174.88 | $149,522.40 |
DisclosureSEC source: 0000950170-23-044413 · ownership.xml · nonDerivative · entry 3 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,052 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.32 to $175.31, inclusive. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 20:49 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 80 | $173.64 | $13,891.20 |
DisclosureSEC source: 0000950170-23-044413 · ownership.xml · nonDerivative · entry 2 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,907 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.31 to $174.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) to this Form 4. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 20:49 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 1,500 | $9.20 | $13,800.00 |
DisclosureSEC source: 0000950170-23-044413 · ownership.xml · nonDerivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:00 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 9,000 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0000950170-23-024286 · ownership.xml · derivative · entry 8 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,726 Underlying: Common Stock · 9,000 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:00 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 782 | $225.93 | $176,677.26 |
DisclosureSEC source: 0000950170-23-024286 · ownership.xml · nonDerivative · entry 7 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,487 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.73 to $226.26, inclusive. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:00 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 1,022 | $225.19 | $230,144.18 |
DisclosureSEC source: 0000950170-23-024286 · ownership.xml · nonDerivative · entry 6 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,269 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.73 to $225.66, inclusive. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:00 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 1,070 | $224.19 | $239,883.30 |
DisclosureSEC source: 0000950170-23-024286 · ownership.xml · nonDerivative · entry 5 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,291 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.72 to $224.71, inclusive. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:00 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 3,309 | $223.21 | $738,601.89 |
DisclosureSEC source: 0000950170-23-024286 · ownership.xml · nonDerivative · entry 4 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,361 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.72 to $223.69, inclusive. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:00 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,093 | $222.24 | $465,148.32 |
DisclosureSEC source: 0000950170-23-024286 · ownership.xml · nonDerivative · entry 3 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,670 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.72 to $222.71, inclusive. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:00 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 724 | $221.28 | $160,206.72 |
DisclosureSEC source: 0000950170-23-024286 · ownership.xml · nonDerivative · entry 2 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,763 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.72 to $221.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (7) to this Form 4. Read SEC document |
| May 23, 2023 Filed May 25, 2023 21:00 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 9,000 | $9.20 | $82,800.00 |
DisclosureSEC source: 0000950170-23-024286 · ownership.xml · nonDerivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2023 Filed Feb 24, 2023 23:40 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | Disposition to issuerStock Option (Right to Buy) · Derivative | 58,823 | Not disclosed Strike: $13.60 | Not disclosed |
DisclosureSEC source: 0001209191-23-012898 · doc4.xml · derivative · entry 2 Ignelzi Troy A. · CIK 0001579829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,823 shares Expires 2031-12-09 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033. F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033. Read SEC document |
| February 24, 2023 Filed Feb 24, 2023 23:40 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | Disposition to issuerStock Option (Right to Buy) · Derivative | 36,324 | Not disclosed Strike: $5.82 | Not disclosed |
DisclosureSEC source: 0001209191-23-012898 · doc4.xml · derivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,324 shares Expires 2031-06-17 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033. F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:37 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 6,000 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001593968-23-000345 · primary_01.xml · derivative · entry 3 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,726 Underlying: Common Stock · 6,000 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:37 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 6,000 | $190.01 | $1,140,060.00 |
DisclosureSEC source: 0001593968-23-000345 · primary_01.xml · nonDerivative · entry 2 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,487 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.96 to $190.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 21:37 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 6,000 | $9.20 | $55,200.00 |
DisclosureSEC source: 0001593968-23-000345 · primary_01.xml · nonDerivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 21:39 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantOption (right to buy) · Derivative | 17,350 | $0.00 Strike: $187.26 | $0.00 |
DisclosureSEC source: 0001593968-23-000304 · primary_01.xml · derivative · entry 2 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,350 Underlying: Common Stock · 17,350 shares Expires 2033-02-08 F2 · derivative.exercise_date: 25% of this option shall vest on February 9, 2024, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 21:39 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantCommon Stock | 8,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-23-000304 · primary_01.xml · nonDerivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,487 F1 · shares: Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest annually in four 25% installments commencing on February 9, 2024, subject to continued service through such dates. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:45 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 200 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001593968-23-000170 · primary_01.xml · derivative · entry 6 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,726 Underlying: Common Stock · 200 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:45 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 200 | $200.14 | $40,028.00 |
DisclosureSEC source: 0001593968-23-000170 · primary_01.xml · nonDerivative · entry 4 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,837 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 21:45 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 200 | $9.20 | $1,840.00 |
DisclosureSEC source: 0001593968-23-000170 · primary_01.xml · nonDerivative · entry 3 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:45 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 817 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001593968-23-000170 · primary_01.xml · derivative · entry 5 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,926 Underlying: Common Stock · 817 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:45 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 817 | $201.41 | $164,551.97 |
DisclosureSEC source: 0001593968-23-000170 · primary_01.xml · nonDerivative · entry 2 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,837 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:45 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 817 | $9.20 | $7,516.40 |
DisclosureSEC source: 0001593968-23-000170 · primary_01.xml · nonDerivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 21:24 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 627 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001593968-22-001741 · primary_01.xml · derivative · entry 6 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626 Underlying: Common Stock · 627 shares Expires 2029-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested as to 1/36th of the shares underlying the option award on each one month anniversary of the vesting commencement date of March 1, 2019. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 21:24 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 371 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001593968-22-001741 · primary_01.xml · derivative · entry 5 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,559 Underlying: Common Stock · 371 shares Expires 2029-03-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested as to 1/36th of the shares underlying the option award on each one month anniversary of the vesting commencement date of March 1, 2019. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 21:24 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 10,869 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001593968-22-001741 · primary_01.xml · derivative · entry 4 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,743 Underlying: Common Stock · 10,869 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vested and became exercisable as to 1/4th of the shares underlying the option award on March 1, 2020, and continues to vest as to an additional 1/8th of the shares on each six month anniversary thereafter. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 21:24 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 627 | $9.20 | $5,768.40 |
DisclosureSEC source: 0001593968-22-001741 · primary_01.xml · nonDerivative · entry 3 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 21:24 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 371 | $9.20 | $3,413.20 |
DisclosureSEC source: 0001593968-22-001741 · primary_01.xml · nonDerivative · entry 2 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 21:24 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 10,869 | $9.20 | $99,994.80 |
DisclosureSEC source: 0001593968-22-001741 · primary_01.xml · nonDerivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:08 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 16,500 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001593968-22-001609 · primary_01.xml · derivative · entry 3 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,612 Underlying: Common Stock · 16,500 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:08 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 16,500 | $225.85 | $3,726,525.00 |
DisclosureSEC source: 0001593968-22-001609 · primary_01.xml · nonDerivative · entry 2 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,970 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 1, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.74 to $225.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:08 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 16,500 | $9.20 | $151,800.00 |
DisclosureSEC source: 0001593968-22-001609 · primary_01.xml · nonDerivative · entry 1 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 23:25 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 400 | $233.20 | $93,280.00 |
DisclosureSEC source: 0001593968-22-001490 · primary_01.xml · nonDerivative · entry 8 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,970 Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 23:25 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 1,100 | $232.00 | $255,200.00 |
DisclosureSEC source: 0001593968-22-001490 · primary_01.xml · nonDerivative · entry 7 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,370 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $232.00 to $232.01, inclusive. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 23:25 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 2,000 | $231.30 | $462,600.00 |
DisclosureSEC source: 0001593968-22-001490 · primary_01.xml · nonDerivative · entry 6 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,470 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.00 to $231.55, inclusive. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 23:25 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 1,000 | $230.02 | $230,020.00 |
DisclosureSEC source: 0001593968-22-001490 · primary_01.xml · nonDerivative · entry 5 Ignelzi Troy A. · CIK 0001579829 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,470 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $230.00 to $230.11, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.